Octagon Capital Advisors LP
CIK: 1839435
Last 13F
Aug 14, 2026
Next 13F
Nov 16, 2026 · in 7 days
Options Notional
$22.99M
Holdings (26)
Q2 2026 13F, quarter ended Jun 30, 2026, filed Aug 14, 2026
- DNTH
DIANTHUS THERAPEUTICS INC
$179.53M
1.84M sh16.48%-5.4% - DFTX
DEFINIUM THERAPEUTICS INC
$138.77M
2.95M sh12.74%+20.9% - ABVX
ABIVAX SA
$132.33M
993,000 sh12.15%+46.7% - COGT
COGENT BIOSCIENCES INC
$90.94M
2.35M sh8.35%+0.0% - ALMS
ALUMIS INC
$79.66M
2.83M sh7.31%+0.0% - AVBP
ARRIVENT BIOPHARMA INC
$68.47M
1.97M sh6.28%+0.0% - TSHA
TAYSHA GENE THERAPIES INC
$66.01M
9.69M sh6.06%+9.4% - BIOA
BIOAGE LABS INC
$42.84M
1.75M sh3.93%+0.0% - MIRM
MIRUM PHARMACEUTICALS INC
$39.68M
338,900 sh3.64%+0.0% - KYMR
KYMERA THERAPEUTICS INC
$35.55M
310,000 sh3.26%-27.1% - AKTS
AKTIS ONCOLOGY INC
$30.97M
960,847 sh2.84%+0.0% - XENE
XENON PHARMACEUTICALS INC
$29.58M
490,000 sh2.71%+0.0% - PALI
PALISADE BIO INC
$21.48M
10.28M sh1.97%+0.0% - OCUL
OCULAR THERAPEUTIX INC
$20.38M
2.08M sh1.87%-34.5% - IRON
DISC MEDICINE INC
$19.75M
270,000 sh1.81%+0.0% - SMMT
SUMMIT THERAPEUTICS INC
$18.21M
1.25M sh1.67%New - PHVS
PHARVARIS N V
$15.79M
456,721 sh1.45%+176.8% - ANL
ADLAI NORTYE LTD
$10.75M
934,716 sh0.99%New - DTIL
PRECISION BIOSCIENCES INC
$10.61M
1.35M sh0.97%-39.6% - DBVT
DBV TECHNOLOGIES S A
$9.42M
574,200 sh0.86%+0.0% - SNSE
FAETH THERAPEUTICS INC
$9.03M
361,010 sh0.83%New - GYRE
GYRE THERAPEUTICS INC
$6.29M
954,416 sh0.58%New - TRVI
TREVI THERAPEUTICS INC
$5.87M
315,000 sh0.54%-78.8% - UNCY
UNICYCIVE THERAPEUTICS INC
$4.69M
1.00M sh0.43%+0.0% - CNTX
CONTEXT THERAPEUTICS INC
$1.69M
3.05M sh0.16%-41.9% - GOSS
GOSSAMER BIO INC
$1.28M
7.75M sh0.12%+0.0%
| Security | Shares | Value | Change | Weight | Period |
|---|---|---|---|---|---|
 DNTH DIANTHUS THERAPEUTICS INC | 1.84M | $179.53M | -5.4% | 16.48% | Q2 2026 |
 DFTX DEFINIUM THERAPEUTICS INC | 2.95M | $138.77M | +20.9% | 12.74% | Q2 2026 |
 ABVX ABIVAX SA | 993,000 | $132.33M | +46.7% | 12.15% | Q2 2026 |
 COGT COGENT BIOSCIENCES INC | 2.35M | $90.94M | +0.0% | 8.35% | Q2 2026 |
 ALMS ALUMIS INC | 2.83M | $79.66M | +0.0% | 7.31% | Q2 2026 |
 AVBP ARRIVENT BIOPHARMA INC | 1.97M | $68.47M | +0.0% | 6.28% | Q2 2026 |
 TSHA TAYSHA GENE THERAPIES INC | 9.69M | $66.01M | +9.4% | 6.06% | Q2 2026 |
 BIOA BIOAGE LABS INC | 1.75M | $42.84M | +0.0% | 3.93% | Q2 2026 |
 MIRM MIRUM PHARMACEUTICALS INC | 338,900 | $39.68M | +0.0% | 3.64% | Q2 2026 |
 KYMR KYMERA THERAPEUTICS INC | 310,000 | $35.55M | -27.1% | 3.26% | Q2 2026 |
 AKTS AKTIS ONCOLOGY INC | 960,847 | $30.97M | +0.0% | 2.84% | Q2 2026 |
 XENE XENON PHARMACEUTICALS INC | 490,000 | $29.58M | +0.0% | 2.71% | Q2 2026 |
 PALI PALISADE BIO INC | 10.28M | $21.48M | +0.0% | 1.97% | Q2 2026 |
 OCUL OCULAR THERAPEUTIX INC | 2.08M | $20.38M | -34.5% | 1.87% | Q2 2026 |
 IRON DISC MEDICINE INC | 270,000 | $19.75M | +0.0% | 1.81% | Q2 2026 |
 SMMT SUMMIT THERAPEUTICS INC | 1.25M | $18.21M | New | 1.67% | Q2 2026 |
 PHVS PHARVARIS N V | 456,721 | $15.79M | +176.8% | 1.45% | Q2 2026 |
 ANL ADLAI NORTYE LTD | 934,716 | $10.75M | New | 0.99% | Q2 2026 |
 DTIL PRECISION BIOSCIENCES INC | 1.35M | $10.61M | -39.6% | 0.97% | Q2 2026 |
 DBVT DBV TECHNOLOGIES S A | 574,200 | $9.42M | +0.0% | 0.86% | Q2 2026 |
 SNSE FAETH THERAPEUTICS INC | 361,010 | $9.03M | New | 0.83% | Q2 2026 |
 GYRE GYRE THERAPEUTICS INC | 954,416 | $6.29M | New | 0.58% | Q2 2026 |
 TRVI TREVI THERAPEUTICS INC | 315,000 | $5.87M | -78.8% | 0.54% | Q2 2026 |
 UNCY UNICYCIVE THERAPEUTICS INC | 1.00M | $4.69M | +0.0% | 0.43% | Q2 2026 |
 CNTX CONTEXT THERAPEUTICS INC | 3.05M | $1.69M | -41.9% | 0.16% | Q2 2026 |
 GOSS GOSSAMER BIO INC | 7.75M | $1.28M | +0.0% | 0.12% | Q2 2026 |
1-26 of 26 holdings
Derivatives (1)
PUT + CALL positions. Value is notional exposure of the underlying, not capital deployed.
- ERASCA INCCall
ERASCA INC
$22.99M
1.25M sh100.00%New
| Security | Type | Shares | Notional | Change | % of Book | Period |
|---|---|---|---|---|---|---|
ERASCA INC ERASCA INC | Call | 1.25M | $22.99M | New | 100.00% | Q2 2026 |
1-1 of 1 derivatives
Sector Allocation
SEC Filings
| Form | Description | Filed |
|---|---|---|
About Octagon Capital Advisors LP
Octagon Capital Advisors LP is an Investment Adviser that reports its US-listed stock and option positions to the SEC on Form 13F (CIK 1839435). Signal8 holds 20 13F filings from it. Its SEC filings list Delaware as its state of incorporation.
Its most recent 13F holdings report covers Q2 2026 (the quarter ended Jun 30, 2026) and was filed on Aug 14, 2026. That report lists 26 securities, not counting options, down from 29 in Q1 2026.
Its five largest reported positions, in order, are DIANTHUS THERAPEUTICS INC (DNTH), DEFINIUM THERAPEUTICS INC (DFTX), ABIVAX SA (ABVX), COGENT BIOSCIENCES INC (COGT) and ALUMIS INC (ALMS). The next five are ARRIVENT BIOPHARMA INC (AVBP), TAYSHA GENE THERAPIES INC (TSHA), BIOAGE LABS INC (BIOA), MIRUM PHARMACEUTICALS INC (MIRM) and KYMERA THERAPEUTICS INC (KYMR).
Recent 13F filings by Octagon Capital Advisors LP
- Q2 2026: 13F-HR filed Aug 14, 2026, listing 26 securities.
- Q1 2026: 13F-HR filed May 15, 2026, listing 29 securities.
- Q4 2025: 13F-HR filed Feb 17, 2026, listing 26 securities.
- Q3 2025: 13F-HR filed Nov 14, 2025, listing 26 securities.
- Q2 2025: 13F-HR filed Aug 14, 2025, listing 30 securities.
- Q1 2025: 13F-HR/A filed May 16, 2025, listing 34 securities.